This PDF is the current document as it appeared on Public Inspection on 09/11/2014 at 08:45 am.
Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing that a collection of information entitled “Eye Tracking Study of Direct-to-Consumer Prescription Drug Advertisement Viewing” has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.Start Further Info
FOR FURTHER INFORMATION CONTACT:
FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.End Further Info End Preamble Start Supplemental Information
On June 30, 2014, the Agency submitted a proposed collection of information entitled “Eye Tracking Study of Direct-to-Consumer Prescription Drug Advertisement Viewing” to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0772. The approval expires on August 31, 2017. A copy of the supporting statement for this information collection is available on the Internet at http://www.reginfo.gov/public/do/PRAMain.Start Signature
Dated: September 8, 2014.
Assistant Commissioner for Policy.
[FR Doc. 2014-21728 Filed 9-11-14; 8:45 am]
BILLING CODE 4164-01-P